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Abstract
Diets low in methionine extend lifespan of rodents, though through unknown mech‐
anisms. Glycine can mitigate methionine toxicity, and a small prior study has sug‐
gested that supplemental glycine could extend lifespan of Fischer 344 rats. We
therefore evaluated the effects of an 8% glycine diet on lifespan and pathology of
genetically heterogeneous mice in the context of the Interventions Testing Program.
Elevated glycine led to a small (4%–6%) but statistically significant lifespan increase,
as well as an increase in maximum lifespan, in both males (p = 0.002) and females
(p < 0.001). Pooling across sex, glycine increased lifespan at each of the three inde‐
pendent sites, with significance at p = 0.01, 0.053, and 0.03, respectively. Glycine‐
supplemented females were lighter than controls, but there was no effect on weight
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in males. End‐of‐life necropsies suggested that glycine‐treated mice were less likely
than controls to die of pulmonary adenocarcinoma (p = 0.03). Of the 40 varieties of
incidental pathology evaluated in these mice, none were increased to a significant
degree by the glycine‐supplemented diet. In parallel analyses of the same cohort, we
found no benefits from TM5441 (an inhibitor of PAI‐1, the primary inhibitor of tissue
and urokinase plasminogen activators), inulin (a source of soluble fiber), or aspirin at
either of two doses. Our glycine results strengthen the idea that modulation of die‐
tary amino acid levels can increase healthy lifespan in mice, and provide a foundation
for further investigation of dietary effects on aging and late‐life diseases.
KEYWORDS

anti‐aging, life span, longevity regulation

1 | I NTRO D U C TI O N

produces significant longevity increases, including survival to the
90th percentile, in both sexes, when started as late as 16 months

Experiments to find drugs or nutritional supplements that can ex‐

of age (Strong, 2016). A third drug, 17‐α‐estradiol (17aE2), a non‐

tend healthy lifespan in mice have four main goals. First, they pro‐

feminizing congener of the well‐known estrogen 17‐β‐estradiol, in‐

vide new models for testing the idea that interventions can retard

creases lifespan of male mice by 19% (Harrison, 2014; Strong, 2016)

multiple aspects of age‐dependent decline, including lethal illnesses

and has a significant effect on survival to the 90th percentile age,

and changes that impair health but seldom lead to death. Second,

but has no significant effect on female mice. Male mice given 17aE2

they give specific biochemical and physiological clues as to the na‐

live significantly longer than female mice whether or not the females

ture of processes that regulate the pace of age‐dependent decline

have been exposed to 17aE2. Lastly, NDGA (nordihydroguaiaretic

in multiple systems. Lifespan extension and health preservation in

acid) has been shown to increase lifespan of male mice only, with an

rapamycin‐treated mice, for example, have prompted valuable stud‐

increase of 12% in median in two independent experimental groups

ies into the role of mTOR, the target of rapamycin, in normal mice

(Strong, 2016; Strong et al., 2008), without a significant effect in fe‐

and in mice with unusual susceptibility to organ‐specific illnesses

male mice. Nordihydroguaiaretic acid, at the doses used, did not lead

(Harrison et al., 2009; Miller et al., 2014; Wilkinson et al., 2012).

to significant changes in survival to the 90th percentile age.

Third, they help guide the search for additional interventions with

Of the other agents tested so far by the ITP, four (methylene blue,

potential beneficial effects. Beneficial effects of acarbose, which in‐

aspirin, Protandim, and green tea extract [GTE]) provided some evi‐

hibits postprandial glucose spikes, can, for example, motivate new

dence for possible health benefits. Methylene blue (Harrison, 2014)

studies of drugs that also modulate glucose transients. Lastly, data

led to a significant (p = 0.004) increase in maximum lifespan that was

on longevity and health outcomes in mice can serve to guide and

limited to females and was not accompanied by alteration in median.

inspire parallel searches for interventions that might, hypothetically,

Aspirin produced an 8% increase in median lifespan (p = 0.01) that

postpone multiple aspects of age‐related decline in humans.

was seen only in male mice, with no significant change in maximal

The NIA Interventions Testing Program (ITP) has to date reported

lifespan by the Wang/Allison test (Strong et al., 2008). Protandim, an

on four drugs with consistent major effects on mouse lifespan in one

inducer of the stress‐resistance factor Nrf2, led to a 7% increase in

or both sexes and found evidence for significant but less dramatic

median lifespan in male mice (Strong, 2016), but there was no effect

effect of four other drugs. Rapamycin, started at 9 months of age,

in females, no effect on maximum lifespan in either sex, and a dra‐

was found to increase median lifespan by as much as 26% in females

matic site‐to‐site variance, with strong lifespan effects seen only at

and 23% in males, and to retard many aspects of age‐related patho‐

the University of Texas Health Science Center at San Antonio (UT)

logical change (Harrison et al., 2009; Miller et al., 2014). Surprisingly,

but not at the Jackson Laboratory (TJL) or University of Michigan

similarly strong lifespan effects were seen even in mice not given

(UM) sites. Green tea extract (Strong et al., 2013) did not show a sig‐

rapamycin until 20 months of age (Harrison et al., 2009). Acarbose

nificant effect by our standard analyses in either sex, but may have

can lead to an increase of 22% in median lifespan in male mice, and

conferred some benefit, in females, against early and mid‐life deaths

to a significant, but smaller, 5% increase in female mice (Harrison,

(p = 0.03 by Wilcoxon–Breslow test, which gives greater weight to

2014; Strong, 2016). Both rapamycin and acarbose improve longev‐

early than to later deaths).

ity in the oldest age‐groups, as indicated by a statistical test that

Diets low in the amino acid methionine have been shown to

compares the proportion of control and drug‐treated mice surviving

extend median and maximum lifespan in rats (Orentreich, 1993;

to the 90th percentile age of the joint distribution, the Wang/Allison

Richie et al., 1994; Zimmerman, 2003) and in mice (Brown‐Borg et

test (Wang, Li, Redden, Weindruch, & Allison, 2004). Acarbose

al., 2014; Miller et al., 2005; Sun, 2009), although it is not yet clearly

|
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F I G U R E 1 Survival curves for glycine‐treated mice, pooled across sites. Each symbol represents one mouse. p‐values calculated by log‐
rank test, stratified by site (for panels with single‐sex data) or by both site and sex (for the panel in which both sexes are combined.)
established if diets deficient in other single amino acids might also

Figure 1 shows survival curves separately for males and for

lead to similar benefits. As a practical matter, interventions that

females, as well as the survival curve for both sexes pooled

involve supplementation of specific nutrients would be easier to

together. Our principal statistical criterion, as in earlier ITP stud‐

test, in humans or mice, than diets that require depletion of specific

ies, is the log‐rank test evaluated separately for each sex (with

compounds. Glycine plays a special role in methionine metabolism,

stratification for site). As shown in Table 1, p = 0.006 for fe‐

serving as the only acceptor for methyl groups, through action of

males and p = 0.002 for male mice by this criterion. When males

glycine‐N‐methyl transferase (GNMT), the key enzyme in the only

and females are combined, the log‐rank test gives p = 0.00004

pathway for methionine clearance in mammals (Luka, Mudd, &

with stratification for site and sex. The effect on median lifes‐

Wagner, 2009). Methionine toxicity can be blocked by dietary gly‐

pan is small: Median survival age increases only 3% in each sex,

cine (Luka et al., 2009), consistent with the notion that GNMT is the

calculated as the average change across the three sites. When

principal effector of methionine clearance, at least at toxic levels.

all the data are pooled for each sex, the change in median is

These data suggest that excess dietary glycine might depress methi‐

4% in females and 6% in males. The average increase in the age

onine levels and thus mimic some of the benefits of a low methionine

at which 90% of the mice have died is 2% for females and 6%

diet. Glycine‐supplemented diets have been reported to produce an‐

for males, calculated as the mean of this value among the three

ticancer and anti‐inflammatory effects in rodents (Alarcon‐Aguilar,

sites. Our statistical criterion for questions about “maximum

2008; Wang et al., 2013; Zhong et al., 2003) and to provide benefits

lifespan” is the test proposed by Wang and Allison (Wang et al.,

in humans with type II diabetes during a 3‐month trial (Cruz, 2008). A

2004), which compares the number of mice in each group that

small study using glycine supplementation in Fisher 344 rats showed

remains alive at the age at which 90% of the mice in the pooled

significant lifespan extension at levels of 8%, 12%, and 20% (Brind,

life table have died. By this test, p = 0.7 for females, p = 0.0005

2011), although the higher glycine levels led to weight loss compared

for males, and p = 0.006 for the combination of males and fe‐

to control rats. Maximum lifespan, evaluated by the Wang/Allison

males. We conclude that 8% glycine diet causes a small lifespan

method, was significantly increased (p = 0.03) only at the 8% supple‐

extension in both sexes, with late‐life effects seen at least in

mentation level. In this earlier experiment, glycine treatment did not

males.

elevate plasma methionine levels, suggesting that the effect was not

The site‐specific data in Table 1 show that glycine caused an

due to minimizing methionine toxicity, but to some other, unknown,

increase in lifespan at each site, with p = 0.013, p = 0.053, and

mechanism.

p = 0.026 at TJL, UM, and UT, respectively, when male and female

We have now conducted a lifespan trial of glycine supplementa‐
tion in a large group of genetically heterogeneous male and female

data are combined. The effect was stronger for females at TJL and
stronger for males at UT in this experiment.

mice, and report here that 8% glycine leads to significant increases in

The glycine‐supplemented diet led to lower weights in female,

longevity in both sexes and at each of three independent test sites.

but not in male, mice, as shown in Figure 2. By 12 months of age,

In the same annual cohort, we found no alteration of lifespan in mice

that is, 3 months after initial exposure to the high glycine diet, fe‐

treated with aspirin (60 or 200 ppm), inulin (600 ppm), or TM5441

male mice were significantly lighter in weight than control animals

(an inhibitor of plasminogen activator inhibitor 1; used at 60 ppm.).

(2.6 g, equivalent to 7% of control weight). Glycine‐treated female
mice were 10% lighter than controls at 18 months, and 9% lighter at

2 | R E S U LT S
2.1 | Increased longevity in male and female mice

24 months, in each case significantly lower than in control females.
Although it is possible that diminished food intake, and thus some
form of caloric restriction, may have affected health in glycine‐
treated females, this explanation seems unlikely to apply to male

Mice given supplemental glycine as 8% of their diet by weight,

mice, in which lifespan effects were equivalent and in which the diet

from age 9 months, survived significantly longer than controls.

did not alter weight trajectory.

Glycine

Control

Glycine

Glycine

Female

Male

Male

Both

Glycine

Control

Glycine

Glycine

Female

Male

Male

Both

Glycine

Glycine

Male

Both

Control

Glycine

Control

Glycine

Glycine

Female

Female

Male

Male

Both

UT

Glycine

Control

Female

Male

Control

Female

UM

Control

Female

TJL

Control

Female

0.026

0.006

0.8

0.053

0.1

0.2

0.013

0.3

0.01

0.00004

0.002

0.006

Log‐rank p‐valuea

810

743

872

882

901

894

925

884

864

873

959

904

884

832

929

897

Median

9

−1

1

5

−1

6

6.2%

3.7%

Change in
medianb

2.9%

3.2%

Site averagec

1,073

977

1,106

1,109

1,138

1,084

1,129

1,139

1,107

1,068

1,190

1,099

1,107

1,059

1,129

1,109

P90 d

10

0

5

−1

4

8

4.5%

1.8%

Change in P90 e

6.2%

2.4%

Site average
(P90)f

0.83

0.04

1.00

0.52

0.13

0.77

0.02

0.27

0.04

0.006

0.0005

0.7

WA p‐valueg

51

99

44

92

51

99

44

92

54

102

48

96

156

300

136

280

Count

Log‐rank p‐values are stratified by site when single‐sex data are evaluated and stratified by site and sex when data from males and females are combined. bChange in median is calculated as [Median for
Glycine minus median for Controls] divided by [Median for controls] pooled across the three test sites, calculated separately for each sex, and expressed as a percentage. c“Site average” is the mean value
of the three site‐specific values for change in median. dP90 is the age at which 90% of the mice had died. e“Change in P90” shows percent difference between glycine and control mice, separately for each
sex. f “Site average” for P90 is the mean value from the three site‐specific calculations of P90. gWA p‐value is derived from Fisher's exact test version of the Wang/Allison procedure, a test of distribution
of control versus glycine mice at the age at which 90% of mice have died in the joint survival distribution. The number of expected and observed dead is evaluated separately at each site (and for each sex,
when pooling over sex), and the counts then added for Fisher's exact test statistic.

a

Rx

Survival statistics for glycine effect, pooled, and site‐specific

Pooled across sites

Sex

TA B L E 1
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TA B L E 2

Summary of cause of death diagnoses

Cause of death

Controls
2

1

Hepatocellular carcinoma

4

3

Lung adenocarcinoma

9

2

Mammary adenocarcinoma

1

2

Metastatic carcinoma

1

5

a

2

2

12

11

Sarcoma (other)

2

2

Soft tissue sarcoma

3

5

Amyloidosis

1

0

Atrial thrombosis

2

3

Endometritis/metritis

2

0

Hepatic necrosis

0

1

Nephritis

2

1

3

1

7

8

53

47

4

4

2

9

Neoplasm (other)

Multiple processes

c

Open
Total (not autolysis)
Autolysis
Autolysis (likely neoplasm)

2.2 | End‐of‐life pathology
Mice in the glycine and control groups were selected (by random
numbers) for necropsy analysis. Tissue sections were evaluated by a
veterinary pathologist (JMS) who was unaware of group assignment.
“Cause of death” diagnoses are summarized in Table 2. Of the 119
specimens submitted, 8 were too severely autolyzed to be evalu‐
ated, and another 11 showed advanced autolysis but with evidence

Glycine

Hemangiosarcoma

Hematopoietic neoplasia (Round
cell tumor, RCT)b

F I G U R E 2 Weights at 6, 12, 18, and 24 months for glycine‐
treated mice, pooled across sites. Symbols show mean values. For
controls, N ~ 96, 91, 83, 70 of each sex at each site, at the ages of 6,
12, 18, and 24 months, respectively, and N for each group of glycine
mice is about 50% of the number of controls. SEM values (not
shown) are <1 g for each age/treatment group, except SEM = 1.6 g
for glycine‐treated male mice at 24 months. Drug effect was
evaluated by a two‐factor ANOVA (site, drug, with interaction
term). The effect of glycine was p > 0.4 for males at each age. For
females, p < 0.004 at ages 12, 18, and 24 months, as indicated by
the asterisks.

5 of 11

d

p‐value

0.03
0.098

0.03

a

Harderian gland adenocarcinoma; a necrotic, hemorrhagic, and throm‐
bosed large subcutaneous neoplasm; a multifocal thoracic neoplasm
with characteristics of both sarcoma and carcinoma; and a liver liposar‐
coma. b17 probably lymphomas; 6 probably histiocytic sarcomas; immu‐
nohistochemistry not performed. c1 severe amyloidosis and lung
adenocarcinoma; 1 pituitary adenoma and atrial thrombosis; 1 lung ade‐
nocarcinoma and stomach squamous cell carcinoma; and 1 RCT and pitu‐
itary adenoma. d7 likely to be hematopoietic (RCT); 1 hepatocellular
carcinoma, 1 lung carcinoma, 1 sarcoma, and 1 hemangiosarcoma.

of lethal neoplasm (details in Note d of Table 2). Of these 19 autolysis
cases, 15 came from a single site (TJL), so TJL cases are somewhat

In addition to evaluation of cause of death, the pathologist noted

under‐represented in the remainder of the table. Of the 100 non‐

“incidental” lesions that were present at time of death but were not

autolyzed cases (53 controls and 47 glycine‐treated), a presumptive

thought to be sufficiently severe to have led to death or terminal

cause of death could be inferred in 81; the other 19 included 4 in

morbidity. Supporting Information Table S2 lists 12 lesions that were

which multiple potentially fatal diseases were present (see Note c in

evaluated on a graded scale, and Supporting Information Table S3

Table 2). and 15 in which no lesion or set of lesions was judged to be

lists the 28 lesions that were listed as present or absent. There were

clearly responsible for the death of the animal.

no significant differences between control and glycine‐treated mice

In the 81 cases in which a likely cause of death was assigned,

for any of these conditions.

glycine‐treated mice were significantly less likely than controls to die
of pulmonary adenocarcinoma limited to the lung (p = 0.03). This is a
lesion that is more often seen in males (seven cases) than in females
(four cases). In addition, we noted that adenocarcinoma limited to

2.3 | Aspirin, inulin, and TM5441 did not lead to
lifespan effects

the lung, as a cause of death, was seen frequently at TJL (five cases)

Many interventions proposed and accepted by the ITP for longevity

and at UT (five cases) but rarely at UM (one case); we do not under‐

testing do not lead to increased lifespan, and ITP policy is to report

stand the reason for this site‐specific effect. Cases with lethal meta‐

these negative effects for all compounds tested. Using the same con‐

static carcinoma, with an unknown primary source, were somewhat

trol mice that were evaluated in the glycine experiment, we evaluated

more common in the glycine group, but the difference did not reach

the possible effects of aspirin (at doses of 60 and 200 ppm), inulin (at

statistical significance (p = 0.098). Some of these may have had lung

600 ppm), and TM5441, an inhibitor of PAI‐1, used at 60 ppm. Each

or liver as a primary source, which might be evaluated by additional

of these was given to the mice starting at age 11 months. Mice were

immunohistochemical methods.

tested at all three sites in roughly equal numbers, as in the glycine

6 of 11
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F I G U R E 3 Survival curves for mice treated with aspirin, inulin, or TM5441, pooled across sites. Left panel: females, pooled across sites.
Right panel: males, pooled across sites

protocol. As shown in Figure 3 and Supporting Information Table S4,

6 months of age. Aspirin is quickly converted to SA once absorbed

none of these treatments led to a significant alteration in longevity

in the small intestine, and mean serum levels of SA in the mice given

in male or female mice, either by our principal criterion the log‐rank

60 ppm were 1.21 ± 1.03 μg/ml (mean ± SD for N = 17), and were

test, or when evaluated by the Wang/Allison method at the 90th

4.1 ± 4.4 in mice given 200 ppm (N = 21). SA levels in mice fed con‐

percentile. None of these agents had any significant effect on weight

trol chow were consistently less than the detection limit of 0.15 μg/

of male mice (not shown). Weight of female mice was unaffected by

ml.

aspirin or inulin, but female mice treated by TM5441 were signifi‐

Three batches of food were tested for levels of TM5441, and

cantly heavier than control females at ages 12, 18, and 24 months

the mean level of drug was 85% of the nominal value. Serum levels

(p < 0.02 at each age; data not shown).

of TM5441 were 198 ng/ml (N = 7, SD = 71) when mice were given
chow containing TM5441 for 11 weeks starting at six months of

2.4 | Assessment of drug and glycine levels in
treated mice

age. As expected, serum from control mice did not contain detect‐
able levels of TM5441 and is thus below the standard curve limit of
1.6 ng/ml.

Four batches of food containing supplemental glycine were evalu‐
ated for glycine content, with an average value of 7.1%, which is
88% of the nominal expected level of 8% glycine. In a pilot experi‐

3 | D I S CU S S I O N

ment, UM‐HET3 mice were given a glycine‐supplemented diet from
10 months of age for a period of 12 weeks. Serum levels of gly‐

Our most interesting new finding is that glycine‐supplemented diets

cine in these glycine‐treated mice were 54 ± 18 μg/ml (mean ± SD;

extend lifespan of male and female UM‐HET3 mice, including sig‐

N = 4), and thus sixfold higher than glycine levels of control mice,

nificant benefits in lifespan to mice at the 90th percentile age. This

which were 9 ± 0.9 μg/ml (N = 4). Similarly, liver levels of glycine

supplementation leads to significant effects at each of the three test

were 1,200 ± 700 ng/mg in the treated mice, fourfold higher than

sites. The result is consistent with an earlier report (Brind, 2011)

in controls (290 ± 40 ng/mg). A second experiment using a separate

showing a beneficial effect of glycine on lifespan (including maxi‐

set of mice produced similar results: 85 versus 14 μg/ml in serum

mal lifespan) in small groups of Fisher 344 rats. The effect in mice,

and 1,900 versus 335 ng/mg in liver. The correlation between serum

although consistent with this prior rat study, is quite small and does

and liver glycine values in the glycine‐fed mice had R2 = 0.94; mice

not much alter median survival age. We speculate that variations

with high serum glycine levels were also relatively high in their liver

in this protocol, for example, in which glycine supplementation is

glycine content. Thus, glycine supplementation of food led to an in‐

started earlier or terminated once mice are fully grown, might have

crease in this amino acid in both serum and liver tissue.

improved effects on health and lifespan.

Aspirin and its breakdown product salicylic acid (SA) were mea‐

Pathology assessment showed that UM‐HET3 mice at end of

sured in three independent batches of food pellets, and the sum

life have a wide variety of age‐related lesions similar to those identi‐

of [aspirin plus SA] was found to be 83% of expected in the pellets

fied in previous longitudinal studies in mice (Harrison, 2014; Snyder,

nominally containing 60 ppm, and 93% of expected levels in pellets

Ward, & Treuting, 2016). Incidental degenerative lesions, presum‐

nominally containing 200 ppm. In a pilot experiment, UM‐HET3

ably related to aging but not a primary cause of death, occurred in

mice were given chow containing aspirin for 11 weeks, starting at

all major organs examined, but did not appear to be influenced by

|
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dietary glycine supplementation. Thus, there is no evidence from

7 of 11

2009). Supplemental glycine, however, was found (Brind, 2011) not

this work that glycine supplementation impairs health. Autolysis

to reduce plasma methionine levels, in contrast to the 60% reduc‐

of organs secondary to carcass preservation technique and post‐

tion in plasma methionine levels seen in rats on a low methionine

mortem autolysis in animals found dead complicated the scoring

diet. This result suggested that elevated glycine levels, in plasma or

of degenerative lesions in many organs. A cross‐sectional study, in

tissues, might in themselves produce health benefits and increased

which mice within a treatment cohort are euthanized and promptly

longevity. Glycine receptors are gated chloride channels that hyper‐

subjected to necropsy with organ removal can be compared with a

polarize plasma membranes and can inhibit cell activation; although

control cohort at the same time point, might show treatment differ‐

they were originally thought to be restricted to the nervous system,

ences, though such a design provides little information about cause

more recent work has demonstrated glycine receptors on many

of death and tends to underestimate the incidence of lesions that

cell types, including macrophages of lung and liver, and platelets

lead to death quickly (Wolf, Giddens, & Martin, 1988).

(Schemmer et al., 2013; Wheeler, 1999). Glycine promotes chloride

Of the 81 cases in which a presumptive cause of death was de‐

influx largely at concentrations (0.5–1 mM) that are considerably

termined, 71 (88%) died as the result of neoplasia, which is similar

higher than those needed for protein synthesis and one‐carbon

to previous studies (Harrison, 2014; Lipman, 2004; Miller & Chrisp,

transfer reactions. Prevention of cell activation and depolarization

2002). Dietary glycine had no effect on these causes of death, ex‐

by maintenance of resting membrane potentials may help to limit

cept for pulmonary adenocarcinoma, where only two mice died in

macrophage activation (Zhong et al., 2003).

the glycine‐supplemented cohort, compared to nine dying from this

Anti‐inflammatory, anticancer, and other putative benefits of

cancer type in mice fed the control diet (p = 0.03). If one includes the

glycine supplementation have been demonstrated in rodent models

two mice (one in each group) in which pulmonary adenocarcinoma

(Alarcon‐Aguilar, 2008; Wang et al., 2013; Yi, Xu, & Allison, 2003),

was considered to be a contributing cause of death, the difference

and one translational study noted benefits in human diabetes trials

in proportion reaches p = 0.06. Pulmonary adenomas were also seen

(Cruz, 2008). A small pilot study had documented a significant lifes‐

more frequently in control animals (a total of 12 neoplasms in nine

pan benefit in inbred rats (Brind, 2011), but our current study pro‐

mice) compared to glycine‐treated animals (a total of seven neo‐

vides more definitive evidence by using a second species, by using

plasms in seven mice), although the difference between groups was

genetically heterogeneous animals, by documenting significant ef‐

not statistically significant. Several mice, especially in the glycine

fects in both males and females, and by showing similar benefits at

group, had metastatic carcinomas which affected the lung in addi‐

each of three independent test sites. The mechanism of effect is not

tion to a variety of other organs. Immunohistochemistry and other

yet known and will require additional targeted work, but could con‐

testing to better characterize the tissue of origin of these neoplasms

ceivably involve lowered inflammation in one or more tissue beds,

were not performed, but one or more of these neoplasms may have

or effects of glycine on CNS processes, or effects, direct or indirect,

arisen from the lung. There was no significant difference between

on multiple forms of lethal neoplastic disease. Consistent with these

the control and glycine groups when all carcinomas involving the

ideas, observational studies have documented lower glycine levels

lung, including metastatic neoplasms, were considered. Cross‐sec‐

in people suffering from diabetes and prediabetes (Guasch‐Ferré et

tional studies in which neoplasms are potentially identified at an

al., 2016), cardiovascular disease (Ding, 2015), and hepatocellular

earlier stage may help define whether glycine exerts a protective

carcinoma (Osman, 2017). Similarly, a recent metabolomics study

effect on the development of pulmonary carcinoma. Hematopoietic

(Hartiala, 2016) reported a 12% decreased risk of coronary artery

neoplasms (round cell tumors) were also a common cause of death

disease (CAD) among female human subjects associated with the

in mice in this study, a category that includes lymphomas and his‐

genetic variant Rs715, which impairs function of the mitochondrial

tiocytic sarcomas. Immunohistochemistry was not performed to

enzyme carbamoyl phosphate synthase (CPS). Carbamoyl phosphate

definitively distinguish between the two. No glycine effect was

synthase catalyzes the first step of the urea cycle, removing ammo‐

seen on the frequency of hematopoietic tumors in these end‐of‐life

nia derived largely from glycine cleavage. Women with the Rs715

necropsies.

variant have elevated plasma glycine levels, which might potentially

Glycine is considered a nonessential amino acid, because it can

contribute to their lower risk of coronary disease.

be synthesized by several pathways, and hence dietary intake pro‐

The present study provides support for the hypothesis that con‐

vides only part of the glycine pool. The endogenous glycine pool is

sumption of glycine in the normal diet may be suboptimal for lon‐

also affected by glycine clearance pathways. A preliminary life‐span

gevity, and that higher levels might be beneficial, perhaps through

study in rats using glycine supplementation (Brind, 2011) was orig‐

moderation of inflammatory processes. The limited data from the

inally conceived as an approach to mimic the well‐established life‐

rat study (Brind, 2011) suggest that higher glycine doses might not

extending effect of methionine restriction (Brown‐Borg et al., 2014;

produce higher benefits, but it is possible that initiation of glycine

Miller et al., 2005; Orentreich, 1993; Richie et al., 2004; Sun, 2009).

supplementation at an earlier age might be worth testing.

The strategy was based on the understanding that glycine is the only

We considered the possibility that extended longevity in the gly‐

acceptor for methyl groups by the action of glycine‐N‐methyl trans‐

cine‐treated mice might reflect low food intake. This seems unlikely,

ferase (GNMT), and that in turn GNMT represents the only path‐

because male mice show extended longevity without small body

way for the clearance of excess methionine in mammals (Luka et al.,

size. Food intake is very difficult to measure accurately, because of
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complications from food wastage into cage bedding, caloric loss in

a later time, or discontinued exposure to the drug after a period of

feces, and variability among mice in the same cage. In addition, small

treatment.

mice eat less food than large mice, because they have diminished the

Aspirin was selected for testing as a follow‐up to our previous

need for thermogenesis; thus, an association between size and food

report (Strong et al., 2008) of lifespan extension in UM‐HET3 male

intake does not demonstrate a causal connection in either direction.

mice given aspirin at 20 ppm from 4 months of age. In the original

We cannot, however, rule out the possibility that glycine supplemen‐

report, we found no effect of aspirin on female longevity, and the

tation might have led to low food intake and to extended longevity in

effect on male longevity (8% increase in median, p = 0.01 by log‐rank

female mice. Incorporation of glycine into the diet lowers its calorie

test) represented benefits seen at the two sites (UT and TJL) in which

density by <1%, which is unlikely to lead to any alteration in nutri‐

male controls were significantly shorter lived than at the third site

tional status or health.
The ITP is committed to reporting the outcome of all longev‐

(UM). To see whether we could obtain larger and more consistent
benefits, we tested mice at doses that were threefold and 10‐fold

ity studies, including those of interventions that did not appear

higher than the dose used in the original ITP report. We found no

to produce health benefits. Three such agents were tested in the

evidence for the benefit of either dose in male or female animals.

same cohort (C2014) that included the glycine‐supplemented

While it is possible that we might have seen a benefit for 60 ppm or

mice.

200 ppm if we had started at an earlier age (4 months, as in the orig‐

TM5441 was selected for testing because it is an orally active,

inal report), and possible that authentic beneficial effects at 20 ppm

small‐molecule inhibitor of PAI‐1, the primary inhibitor of tissue

are lost at the higher doses, our preferred interpretation is that the

and urokinase plasminogen activators, and thus a primary effector

original report reflected a type I error and that aspirin does not re‐

of fibrinolysis and extracellular proteolysis (Boe, 2013). PAI‐1 lev‐

liably confer increased lifespan in these genetically heterogeneous

els increase with age in mice and humans (Khan, 2017; Testa et al.,

mice.

2009; Yamamoto et al., 2002) and are increased by obesity, insulin
resistance, and inflammation (Alessi & Juhan‐Vague, 2006; Khan,
2017). PAI‐1 is present in atherosclerotic plaques and accumulates
with age in murine heart muscle (Sobel, Lee, Pratley, & Schneider,
2006). PAI‐1 appears to contribute to common cardiovascular man‐
ifestations of aging. PAI‐1 excess is prothrombotic, and PAI‐1 ap‐

4 | M E TH O DS
4.1 | Mouse husbandry
The ITP protocol for longevity studies has been described exten‐

pears to be an important contributor to arteriosclerosis and vascular

sively elsewhere (Miller et al., 2014; Strong, 2016), with details on

stiffness (Lieb et al., 2009). A recently published Mendelian analysis

source of food, bedding, cage changes, light/dark cycle, and other

concluded that PAI‐1 plays a causal role in coronary heart disease

husbandry details. In brief, mice are bred as the progeny of (BALB/

(Song, 2017). PAI‐1 is elevated in the klotho (kl/kl) mutant mouse

cByJ × C57BL/6J)F1 mothers and (C3H/HeJ × DBA/2J)F1 fathers,

and in the BubR1H/H mutant, mice which some have interpreted as

so that each mouse is genetically unique and a full sib to all other

models of accelerated aging, and administration of TM5441 extends

mice with respect to segregating nuclear alleles. Mice are housed

median lifespan of klotho mice (Eren et al., 2014). We hypothesized

at three males or four females per cage from weaning, without re‐

that inhibition of PAI‐1 by TM5441 would lead to extended lifespan

placement as mice die at older ages. They are given free access to

in normal mice, but found no evidence for higher lifespan in UM‐

food and water. Purina 5LG6 is used as the base diet from weaning,

HET3 mice treated from 11 months of age.

with drugs and supplements given at the concentrations shown in

Inulin was selected for testing because it had shown preliminary

Supporting Information Table S1. Mice are weighed at ages 6, 12,

evidence for lifespan benefit in a large‐scale screen using female

18, and 24 months, but are otherwise undisturbed. If fight wounds

B6C3F1 mice. In this unpublished screen, over 1,000 drugs and re‐

require that mice be removed for humane reasons, all the mice in the

lated molecules were tested in parallel using a shared control group.

affected cage are removed from the study, so as not to enrich for

Drugs were administered from 5 months of age at doses 50%–100%

dominant or nondominant individuals. Mice that are removed from

of the maximum recommended therapeutic dose for human patients.

the study, either for fighting or for other technical reasons (e.g., chip

In this survey, inulin at 600 ppm was found to extend mean and max‐

ID dysfunction, escape, accidental injury), are treated as known to

imal lifespan by 16%, with p = 0.06 for the mean value compared to

be alive on the day of removal and lost to follow‐up at that point.

control females. Inulin is a soluble fiber, derived from chicory root,

Mice are inspected daily, and those which are deemed to be unlikely

that is metabolized by gut bacteria, and is hypothesized to promote

to live for more than another 24 hr, based on a symptom checklist,

host health by improvements in the balance of species within the gut

are euthanized for humane reasons, with the day of euthanasia taken

microbial populations. There is some previous evidence that inulin

as the best estimate of the date of natural death for statistical pur‐

can extend rat lifespan (Rozan et al., 2008). Our own data did not

poses. Date of death is also recorded for those found dead. Sentinel

provide any evidence for health benefits of inulin when given from

mice are tested for antibodies against pathogenic viruses and for

11 months of age to male or female UM‐HET3 mice. It is possible

parasites, either annually or quarterly depending on the pathogen,

that a beneficial effect of TM5441 or inulin might have been seen

and all such tests were negative at each test site throughout the pe‐

had we use a different dose, started at an earlier time, started at

riod of this study.
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4.2 | Estimation of glycine, TM‐5441, aspirin, and
salicylic acid in food and tissue samples

9 of 11

error of the difference under the null hypothesis. For significance
tests of graded pathology findings, we used the Student's t test.
Significance was assigned with respect to the arbitrary benchmark

Glycine levels were measured in food, serum, and liver tissue using an

of p = 0.05 in two‐sided tests, without adjustment for multiple

LC/MS/MS system (a Shimadzu SIL 20A HT autosampler, LC‐20AD

comparisons.

pumps, and an AB Sciex API 3200 tandem mass spectrometer with
turbo ion spray). Serum standard curves were obtained by spiking
normal serum at concentrations from 5 to 160 μg/ml. Liver glycine

AC K N OW L E D G M E N T S

concentrations were estimated in a similar way using sonicated tis‐

This work was supported by NIA grants AG022303, AG047115,

sues, with calibration standards between 63 and 1,000 ng/mg. LC/

AG022307, AG022308, CA034196, and AG013319. RS is supported

MS/MS methods for quantitating TM‐5441 in serum and in food pel‐

by a Senior Research Career Scientist Award from the Department

lets used standards purchased from Tocris Bioscience (Minneapolis,

of Veterans Affairs Office of Research and Development. We thank

MN). Estimation of aspirin and salicylic acid levels used standards

Roxann Alonzo, Ilkim Erturk, Natalie Perry, Lori Roberts, Greg

purchased from Sigma Chemical Company (St. Louis, MO). We were

Friesenhahn, Vivian Diaz, Kateryna Tonyuk, P. Reifsnyder, J. Krason,

unable to develop an assay for inulin in serum, because inulin con‐

V. Ingalls, and N. Durgin for technical assistance.

sists of a complex mixture of polysaccharides of different molecular
sizes.

4.3 | Terminal necropsies

C O N FL I C T O F I N T E R E S T
Joel Brind: Natural Food Science, LLC, makes and sells a glycine sup‐
plement product.

Mice dying (or euthanized when terminally ill) were fixed using a pro‐
cess in which incisions were made in cranium, thorax, and abdomen,
and the carcass immersed in 10% neutral‐buffered formalin, and
then kept at room temperature for a period of up to 4 years. Glycine‐
treated and control cases were then selected by a random number
table, selecting 10 male and 10 female glycine‐treated mice from
each test site, plus an equal number of control mice. Each animal was
given a code so that the assessment of lesions could be conducted
by a veterinary pathologist blinded to the treatment group, and
the specimens were then shipped to the Geropathology Research
Program at University of Washington for necropsy and histopatho‐
logical analysis. A detailed description of procedures and diagnostic
criteria is given in the Supplemental Methods section.

4.4 | Statistical testing
Drug effects on lifespan are evaluated by the log‐rank test, strati‐
fying by site, separately for males and females. For analyses com‐
bining male and female survival data, the log‐rank test includes
stratification by both sex and site. These data sets include mice
that have died, mice removed for fighting or other cause, and mice
still alive at the time of evaluation. Estimates of median survival
age and of the age at which 90% have died include only live and
dead, but not removed, mice. Hypotheses about survival to very
old age are done by the method of Wang and Allison (Wang et
al., 2004), using Fisher's exact test. Effects of interventions on
body weight are evaluated separately in each sex by a two‐factor
ANOVA (drug, site, and interaction terms), with the p‐value for the
drug effect taken as the key outcome. For the significance tests
of group differences in the proportion of mice with specific forms
of pathology, we used the “prtest” (proportions test) module of
Stata, which computes a normally distributed z‐statistic as the
difference between the two proportions divided by the standard
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S U P P O R T I N G I N FO R M AT I O N
Additional supporting information may be found online in the
Supporting Information section at the end of the article.
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